Baldwin Wealth Partners LLC MA Decreases Stake in Novo Nordisk A/S (NYSE:NVO)

Baldwin Wealth Partners LLC MA cut its position in Novo Nordisk A/S (NYSE:NVO) by 11.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 48,708 shares of the company’s stock after selling 6,547 shares during the period. Baldwin Wealth Partners LLC MA’s holdings in Novo Nordisk A/S were worth $4,190,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of NVO. International Assets Investment Management LLC increased its holdings in Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after buying an additional 1,796,635 shares during the last quarter. Mediolanum International Funds Ltd purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $98,765,000. Wellington Management Group LLP acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $42,017,000. Sanctuary Advisors LLC purchased a new stake in Novo Nordisk A/S during the second quarter worth approximately $41,646,000. Finally, World Investment Advisors LLC boosted its holdings in Novo Nordisk A/S by 2,655.9% in the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after purchasing an additional 270,234 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on NVO. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $86.57 on Monday. The business’s 50-day moving average price is $95.35 and its 200 day moving average price is $114.80. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm has a market cap of $388.46 billion, a P/E ratio of 28.04, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.